Company Profile
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
Latest News
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Website | https://www.wuxiapptec.com |
| Market Cap | 371.96B |
| Trailing P/E | 18.04 |
| Forward P/E | 17.18 |
| Dividend Rate | 1.93 |
| Dividend Yield | 1.54% |
| Trailing Annual Div. Rate | 1.93 |
| Trailing Annual Div. Yield | 1.54% |
| Trailing EPS | 6.91 |
| Forward EPS | 7.26 |
| Book Value | 28.23 |
| Price-to-Book | 4.42 |
| Enterprise-to-Revenue | 7.3 |
| Enterprise-to-EBITDA | 15.44 |
| Ex-Dividend Date | 05/29/2026 |
| Earnings Date | |
| Earnings Call Date | |
| Revenue Average | 13.15B |
| Revenue Low | 13.11B |
| Revenue High | 13.19B |